Trials / Completed
CompletedNCT00127296
Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe
Comparison of the Accuracy and Precision of NovoLog® Mix 70/30 FlexPen® to Vial and Syringe in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 40 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this trial - insulin is dispensed into an empty vial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | FlexPen® | |
| DEVICE | vial and syringe |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2005-08-05
- Last updated
- 2017-01-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00127296. Inclusion in this directory is not an endorsement.